COLO-RECTAL CANCER (DMMR/MSI-H CRC)
Clinical trials for COLO-RECTAL CANCER (DMMR/MSI-H CRC) explained in plain language.
Never miss a new study
Get alerted when new COLO-RECTAL CANCER (DMMR/MSI-H CRC) trials appear
Sign up with your email to follow new studies for COLO-RECTAL CANCER (DMMR/MSI-H CRC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug before surgery may shrink hard-to-treat colorectal cancers
Disease control Recruiting nowThis study looks at whether giving the drug tislelizumab before surgery can help people with a specific genetic type of colorectal cancer (dMMR/MSI-H). About 30 adults with stage II or III cancer will receive three doses of tislelizumab, then have surgery to remove the tumor. Res…
Matched conditions: COLO-RECTAL CANCER (DMMR/MSI-H CRC)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 26, 2026 10:55 UTC
-
Shot vs. drip: cancer patients pick their preferred way to get immunotherapy
Knowledge-focused Recruiting nowThis study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…
Matched conditions: COLO-RECTAL CANCER (DMMR/MSI-H CRC)
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Knowledge-focused
Last updated May 07, 2026 18:39 UTC